Last reviewed · How we verify
NCT02464215: SWEET
Effect of Laparoscopy-Assisted Distal Gastrectomy for Locally Advanced Gastric Cancer
Status unknown
NA
Last updated 12 May 2020
What this trial tests
NA trial testing open surgery in Gastric Cancer in 440 participants. Status unknown.
Timeline
1 March 2014
Primary endpoint
31 August 2020
31 August 2020
31 August 2020
Quick facts
| Lead sponsor | Peking University Cancer Hospital & Institute |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 440 |
| Start date | 1 March 2014 |
| Primary completion | 31 August 2020 |
| Estimated completion | 31 August 2020 |
| Sites | 1 location across China |
Drugs / interventions tested
- open surgery
- laparoscopic surgery
Conditions studied
- Gastric Cancer — all drugs for Gastric Cancer →
Sponsor
Peking University Cancer Hospital & Institute
Who can join
18 and older, any sex, with Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the effect and safety of laparoscopy-assisted D2 radical surgery for distal advanced gastric cancer.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Short-term surgical outcomes of laparoscopy-assisted versus open D2 distal gastrectomy for locally advanced gastric cancer in North China: a multicenter randomized controlled trial.
Wang Z, Xing J, Cai J, Zhang Z, et al · · 2019 · cited 56× · PMID 30386984 · DOI 10.1007/s00464-018-6391-x -
Long-term outcomes of laparoscopic versus open distal gastrectomy for patients with advanced gastric cancer in North China: a multicenter randomized controlled trial.
Xing J, Cai J, Wang X, Zhang N, et al · · 2024 · cited 3× · PMID 38981881 · DOI 10.1007/s00464-024-10952-2 -
Landscape of interventional clinical trials involving gastrectomy for gastric cancer.
Khachfe HH, Salhab HA, Fares MY, Chahrour MA, et al · · 2021 · cited 1× · PMID 34158822 · DOI 10.3332/ecancer.2021.1218 -
Current clinical trials on gastric cancer surgery in China.
Zhang S, Hu RH, Cui XM, Song C, et al · · 2024 · PMID 39554743 · DOI 10.4251/wjgo.v16.i11.4369
Verify or expand the search:
- PubMed search for NCT02464215
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of open surgery
Trials testing the same drug.
- NCT06822270 — Different Surgical Modalities in the Management of Pelvi-ureteric Junction Obstruction · NA · active not recruiting
- NCT05894915 — Study and Transformation of Tumor Molecular Features Screening Model of Endometrial Carcinoma Surgical Approach · NA · unknown
- NCT03895723 — Minimally Invasive Versus Open Liver Resection for Patients With Colorectal Cancer Liver Metastases · NA · unknown
- NCT07177222 — Compare the Quality of Life of Patients With Achalasia Cardia (AC) After Laparoscopic and Open Esophagocardiomyotomy. · completed
- NCT03297099 — Robotic-Assisted Laparoscopic Versus Open Surgery for Complicated Hepatolithiasis · NA · unknown
Other recruiting trials for Gastric Cancer
Currently open trials in the same condition.
- NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
- NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
- NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting
Other Peking University Cancer Hospital & Institute trials
Trials by the same sponsor.
- NCT07527806 — Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Im · Phase 2 · not yet recruiting
- NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors · recruiting
- NCT07417241 — SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study · Phase 2 · not yet recruiting
- NCT07470203 — Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer · not yet recruiting
- NCT07394192 — Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS Stage II-I · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT02464215 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking University Cancer Hospital & Institute
- Last refreshed: 12 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02464215.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing